Novartis AG (NVS)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 89.84 |
| Open | 89.34 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 1000 |
| Day's range | 89.27 - 89.99 |
| 52-week range | 74.09 - 94.26 |
| Volume | |
| Avg. volume | 2,004,071 |
| Market cap | 193.093B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 9.23 |
| EPS (TTM) | 9.70 |
| Earnings date | N/A |
| Forward dividend & yield | 3.33 (3.70%) |
| Ex-dividend date | 08 Mar 2022 |
| 1y target est | 104.25 |
- Motley Fool
Could This Be Novartis' Next Blockbuster Medicine?
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.
- Zacks
Novartis' (NVS) Unit to Acquire Astellas' Rights of Mycamine
Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.
- Globe Newswire
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly reinforce Sandoz hospital offering and leading anti-infectives portfolioAddition of Mycamine® will support Sandoz global program to combat antimicrobial resistance (AMR) by targeted use of most appropriate therapies Basel, January 24, 2023 – Sandoz, the global leader in off-patent (generic and biosimilar)
© 2023 Yahoo. All rights reserved.
